Dr. Reddy's Laboratories

Traded on the St. Petersburg Stock Exchange
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.
Dr. Reddy's Laboratories stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Dr. Reddy's Laboratories balance sheet

Report period2018 2019 2020 2021 2022Q1 24
End date of the reporting period
Capitalization, ₹
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Dr. Reddy's Laboratories cash flows

Report period2018 2019 2020 2021 2022Q1 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Dr. Reddy's Laboratories multipliers

Report period2018 2019 2020 2021 2022Q1 24 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Dr. Reddy's Laboratories profitability

Report period2018 2019 2020 2021 2022Q1 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Dr. Reddy's Laboratories assets
Dr. Reddy's Laboratories cash flows
Dr. Reddy's Laboratories dividends
0%

Dr. Reddy's Laboratories dividend policy

The company pays dividends on a quarterly basis.

Dr. Reddy's Laboratories shares

TickerNameTypeNominal valueISINPrice
RDY:USDr. Reddy's Laboratories Ltd.Depositary receipt-US2561352038$73.48
Dr. Reddy's Laboratories news
20.05.2022
Dr. Reddy's Laboratories' IFRS net income for fiscal year 2022 was ₹23.568 billion, up 36.7% from ₹17.238 billion the previous year. Revenue increased 13% to ₹214.391 billion compared to ₹189.722 billion a year earlier.
21.02.2022
Dr. Reddy's is selling to Binnopharm Group, part of Sistema, the right to sell Ciprolet and Levolet antibacterial drugs in Russia, Belarus and Uzbekistan. At the initial stage Dr. Reddy's will supply the drugs to the Russian company, and in the future their production will be localized at the facilities of Binnopharm Group. The terms of the deal were not dis...
31.01.2022
Dr. Reddy's Laboratories IFRS net income for 9 months of fiscal 2022 was ₹22.693 billion, up 66.7% from ₹13.614 billion in the previous year. Revenue rose 12.3% to ₹160.023 billion compared to ₹142.438 billion a year earlier.
04.01.2022
Indian drug maker Dr. Reddy's Laboratories will release a generic of molnupiravir, a tablet from Merck's COVID-19. The drug will be sold under the brand name Molflu. The total cost of a 5-day course of treatment, consisting of 40 capsules, will be ₹1,400, or $18.77, while the original Merck pills cost $700. Molflu sales across India are scheduled to begin ne...
General information
Company nameDr. Reddy's Laboratories
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address8-2-337, ROAD NO.3 BANJARA HILLS HYDERABAD K7 500-034 91 40 49002900
Mailing address8-2-337, ROAD NO.3 BANJARA HILLS HYDERABAD K7 500-034
Websitewww.drreddys.com